Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | KIF11 | P52732 | 9/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8784660 | 1.00 | CA4 (0.54) | CA4LTA4HKIF11KCNH2CA12 | |
| Bromide SCHEMBL31164184 | 0.98 | CA4 (0.52) | CA4LTA4HKIF11KCNH2CA12 | |
| Hydrochloric Acid SCHEMBL30389842 | 0.98 | CA4 (0.52) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL8784562 | 0.91 | CA1 (0.58) | CA4LTA4HCA12CA1CA2 | |
| SCHEMBL136229 | 0.87 | CA4 (0.54) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL434969 | 0.87 | CA4 (0.54) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL14999927 | 0.86 | ALDH1A1 (0.61) | CA4LTA4HKIF11KCNH2TRPA1 | |
| Methoxytriphenylmethane SCHEMBL9103 | 0.86 | MAPK1 (0.48) | CA4KIF11CES1CYP19A1 | |
| Methoxytriphenylmethane SCHEMBL27882817 | 0.84 | MAPK1 (0.46) | CA4KIF11CES1CYP19A1 | |
| Nitrobenzene SCHEMBL28241110 | 0.83 | ALDH1A1 (0.48) | KCNH2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116056762-A | Compositions comprising benzoates of 5-methoxy-N, N-dimethyltryptamine | 贝克利心理科技有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20230096856-A1 | COMBINED TREATMENT REGIMEN OF ANESTHESIA/SEDATION WITH ADMINISTRATION OF PSYCHEDELIC DRUGS ASSOCIATED WITH REDUCTION IN NEUROPSYCHIATRIC ILLNESS | Pillar Clinical Research, LLC (US) | 2023-03-30 | — | — | US | claimed |
| WO-2023019354-A1 | ISOTOPICALLY LABELED TRYPTAMINES AND ANALOGS THEREOF | BIOMIND LABS INC (CA) | 2023-02-23 | — | — | WO | claimed |
| CN-108610360-A | Phosphoramidite and its preparation method and application | 中国石油大学(华东) | 2018-10-02 | — | — | CN | claimed |
| US-20030129589-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. | 2003-07-10 | — | — | US | claimed |
| US-20020042112-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. | 2002-04-11 | — | — | US | claimed |
| US-RE37623-E1 | PHENYLTHIO AND PHENYLSELENO PYRIMIDINE ANALOGS | el Kouni, Mahmoud H. | 2002-04-02 | — | — | US | claimed |
| EP-0954612-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998020166-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | claimed |
| EP-0725641-A4 | — | — | 1996-09-04 | — | — | EP | claimed |
| EP-0725641-A1 | NOVEL ENZYME INHIBITORS, THEIR SYNTHESIS, AND METHODS FOR USE | El Kouni, Mahmoud H. (US) | 1996-08-14 | — | — | EP | claimed |
| US-5476855-A | Pyrimidine analogs and nucleosides | el Kouni, Mahmoud H. (US) | 1995-12-19 | — | — | US | claimed |
| WO-1995012400-A1 | NOVEL ENZYME INHIBITORS, THEIR SYNTHESIS, AND METHODS FOR USE | UAB RESEARCH FOUNDATION (US) | 1995-05-11 | — | — | WO | claimed |
| US-12612363-B2 | Recrystallisation of 5-methoxy-N,N-dimethyltryptamine(5-MeO-DMT) | GH Research Ireland Limited (IE) | 2026-04-28 | — | — | US | disclosed |
| WO-2026068950-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-MEO-DMT FOR USE IN THE TREATMENT OF ALCOHOL USE DISORDERS | Beckley Psytech Limited (GB) | 2026-04-02 | — | — | WO | disclosed |
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| WO-1998020020-A2 | HIGH DENSITY IMMOBILIZATION OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| EP-0703498-B1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEM CORP (JP) | 1997-12-29 | — | — | EP | disclosed |
| US-5698362-A | CONTAINING A TRIARYLMETHANE DERIVATIVE; HIGH RESOLUTION, EXCELLENT IN DEPTH OF FOCUS AND PATTERN PROFILE, STORAGE STABLE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0703498-A1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078372-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL | LPAR2, LPCAT1, LPAR1 | CA4 4534/4885LTA4H 1487/4885KIF11 2193/4885 |
| US-12612363-B2 | Recrystallisation of 5-methoxy-N,N-dimethyltryptamine(5-MeO-DMT) | HTR2A, HTR5A, HTR2C | CA4 3788/4885LTA4H 1650/4885KIF11 3910/4885 |
| US-20020042112-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | DNA2, DDB1, DNMT3A | CA4 2001/4885LTA4H 2565/4885KIF11 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.